PROGRAMMED USE OF EXTRACORPOREAL PHOTOCHEMOTHERAPY IN THE COMPLEX TREATMENT OF DEVERGEY'S DISEASE

DOI: https://doi.org/10.29296/25877313-2020-08-05
Issue: 
8
Year: 
2020

Manuilov A.S. Senior Resident of the Clinic for Nephrology and Efferent Therapy, Military Medical Academy named after S.M. Kirova (St. Petersburg) E-mail: andre.manuilov@yandex.ru A.N.Belsky Dr.Sc. (Med.), Professor, Corresponding Member RAS, Head Department of Nephrology and Efferent Therapy, Military Medical Academy named after S.M. Kirova (St. Petersburg) Email: belsky@gmail.com S.N. Bardakov Ph.D. (Med.), Lecturer at the Department of Nephrology and Efferent Therapy, Military Medical Academy named after S.M. Kirova (St. Petersburg) E-mail: epistaxis@mail.ru A.V. Apchel Dr.Sc. (Med.), Associate Professor of the Department of Skin and Sexually Transmitted Diseases, Military Medical Academy named after S.M. Kirova (St. Petersburg) E-mail: apchelandrey@mail.ru

Relevance. One of the promising areas of modern medicine is the method of efferent therapy, selectively affecting the mechanisms of the immune system and homeostasis. The lack of effectiveness of drugs, their side effects and the emerging pharmacoresistance in patients with Devergy dis-ease, contribute to the search for new methods of treatment based on extracorporeal photochemical treatment of peripheral blood cells. Objective. To study the clinical and pathogenetic significance of the programmed use of extracorporeal photochemotherapy in the complex treat-ment of Devergey's disease. Material and methods. Using the method of extracorporeal photochemotherapy, a programmed treatment of a patient with Devergy disease was carried out for 12 months. Results. In an in vitro study with incubation of cell media, it was found that the extracorporeal photochemotherapy technique induces lymphocyte apoptosis with maximum levels on the third day after the procedure, which confirms the pathogenetic significance of this technique in the complex treatment of patients with Devergee's disease. Conclusions. The inclusion of programmed extracorporeal photochemotherapy in the complex therapy of a patient with Devergey's disease made it possible to stop a very high activity of the disease, reduce the dosage of acetritin preparations and achieve long-term remission (more than 12 months of observation).

Keywords: 
extracorporeal photochemotherapy
apoptosis
Devergey's disease
T-lymphocytes
cellular immunity
immune response

References: 
  1. Ipe T., Pham N., Williams L. Critical updates in the 7th edition of the American society for apheresis guidelines. J. Clin. Apher. 2018; 33 (1): 78–94.
  2. Knobler R., Barr M., Couriel D., Ferrara J., French L., Jaksch P., Reinisch W., Rook A., Schwarz T., Greinix H. Extracorporeal photopheresis: past, present, and future. J. Am. Acad. Dermatol. 2009; 61 (4): 652–665.
  3. Song P., Tarley K. Photochemistry and photobiology of psoralens. Photochem. Photobiol. 1979; 29: 1177–1197.
  4. Trautinger F., Just U., Knobler R. Photopheresis (extracorporeal photochemotherapy). Photochem. Photobiol. 2013; 12 (1): 22–28.
  5. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., Plewig G. Treatment of cutaneous T–cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med. 1987; 316 (6): 297–303.
  6. Chiesa-Fuxench Z.C., Gonzalez-Chavez J.P. Extracorporeal photopheresis: a review on the immunological aspects and clinical applications. R. Health. Sci. J. 2010; 29 (4): 337–347.
  7. Voss C., Fry T., Coppes M., Blajchman M. Extending the horizon for cellbased immunotherapy by understanding the mechanisms of action of photopheresis. Transfus. Med. Rev. 2010; 24 (1): 22–32.
  8. Schooneman F. Extracorporeal photopheresis technical aspects. Transfus. Apher. Sci. 2003; 28 (1): 51–61.
  9. Wolnicka-Glubisz A., Fraczek J., Skrzeczynska-Moncznik J., Friedlein G., Mikolajczyk T., Sarna T., Pryjma J. Effect of UVA and 8-methoxypsoralen 4, 6, 4' trimethylangelicin or chlorpromazine on apoptosis of lymphocytes and their recognition by monocytes. J. Physiol. Pharmacol. 2010; 61 (1): 107–114.
  10. Knobler R., Berlin G., Calzavara-Pinton P. Guideline on the use extracorporeal photopheresis. JEADV. 2014; 28 (1): 1–37.
  11. Prinz B., Nachbar F., Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch. Dermatol. Res. 1994; 287 (1): 48–52.
  12. Harman K., Albert S., Black M. British association of dermatologists. Guidelines for the management of pemphigus vulgaris. Br. J. Dermatol. 2003; 149 (5): 926–937.
  13. Miller J., Stricklin G., Fine J., King L., Arzubiaga M., Ellis D. Remission of severe epidermolysisbullosaacquisita induced by extracorporeal photochemotherapy Br. J. Dermatol. 1995; 133 (3): 467–471.
  14. Becherel P., Bussel A., Chosidow O., Rabian C., Piette J., Frances C. Extracorporeal photochemotherapy for chronic erosive lichen planus. Lancet. 1998. 351 (9105): 805.
  15. Haenssle H., Bertsch H., Emmert S., Wolf C., Zutt M. Extracorporeal photochemotherapy for the treatment of exanthematicpityriasisrubrapilaris. Clin. Exp. Dermatol. 2004. 29 (3): 244–246.
  16. Griffiths W. Pityriasisrubrapilaris. Clin. Exp. Dermatol. 1980; 5: 105–112.
  17. Akiyama M., Takeichi T., McGrath J., Sugiura K. Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin. J. Dermatol. Sci. 2018; 90 (2): 105–111.
  18. Mainardi L., Caccialanza M., Piccinno R. Efficacy of photochemotherapy in a case of pityriasisrubrapilaris. G. Ital. Dermatol. Venereol. 1990; 125 (11): 537–538.
  19. Hofer A., Mullegger R., Kerl H., Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermicpityriasisrubrapilaris. Arch. Dermatol. 1999; 135 (4): 475–476.